Pricing
Competitive Pricing at Every Volume
Avanta Pharma Group works through established 503A pharmacy partner relationships and combines purchasing volume across the clinics it supplies to negotiate rates that scale. Whether a practice orders a couple of dozen vials a month or several hundred, pricing is banded rather than gated behind a large minimum commitment, and the entry band is orderable at published list pricing without a call.
- Band 125-49 orders a month$80 per vial: list price, orderable with no call
- Band 250-99 orders a month$75 per vial
- Band 3100-199 orders a month$70 per vial
- Band 4200+ orders a month$65 per vial, the lowest published price
Published list pricing
- Semaglutide 1 mL (2.5 mg/mL)
- from $65per vial at 200+ a month
- Tirzepatide 1 mL (10 mg/mL)
- from $100per vial
- List pricing orderable with no call
- Volume pricing quoted on a call
- Shipping $25 standard, $45 overnight
- To the clinic or direct to the patient
Of the 19 suppliers Clinic Partner Guide tracks (12 sourcing platforms and 7 pharmacies), 2 publish per-vial rates a clinic can read before making contact, and Avanta Pharma Group is one of them. Most of this market quotes only after a call or a provider account, which is why the figures above are unusual rather than ordinary. They are Avanta Pharma Group’s own published list rates, read from its site on 2026-10-22, and you can check them there.
Rates shown are Avanta Pharma Group’s published list pricing and may change. Volume pricing is quoted per clinic, so the rate a practice pays depends on its own monthly volume, formulation and terms. Avanta Pharma Group is a pharmacy sourcing partner: compounding is performed by its 503A pharmacy partners rather than by Avanta Pharma Group itself.
Reading an FDA warning-letter page for your supplier file: letter date, "Content current as of", close-out, and the recall column
As of 30 October 2026, FDA's warning-letter index says matters in a letter may have been subject to later interaction that may have changed their regulatory status. So file facts, not a verdict: the letter date, the page's "Content current as of" date, whether a close-out letter is listed, and, for a 503B outsourcing facility, the recall cell in FDA's table. Date each read.
Contents
- How does a clinic look up, and file, what FDA has posted about a supplier?
- In short: five steps
- Disclosure
- What FDA's own pages say, read 30 October 2026
- Key points
- Overview
- Three dates, three fields
- Key points
- Overview
- A missing close-out letter: what it records, and what it does not show
- The outsourcing-facility table: recall and Form 483 cells
- Five steps, and what to ask the supplier in writing
- How it works
- The row to keep in your supplier file
- Key points
- Overview
- What this page does not cover
- Questions clinics ask
- Use it with
- Sources
How does a clinic look up, and file, what FDA has posted about a supplier?
As of 30 October 2026, FDA's warning-letter index says matters in a letter may have been subject to later interaction that may have changed their regulatory statusSource 1. So file facts, not a verdict: the letter date, the page's "Content current as of" date, whether a close-out letter is listed, and, for a 503B outsourcing facility, the recall cell in FDA's tableSource 3. Date each read.
This is a record-keeping routine. Clinic Partner Guide names no pharmacy here and draws no conclusion from any letter, close-out or recall entry.
In short: five steps
As of 30 October 2026: (1) search FDA's warning-letter index by the supplier's legal name and any "doing business as" name; (2) record the letter date, posted date and "Content current as of" date separately; (3) note whether a close-out letter is listedSource 1; (4) for a 503B outsourcing facility, record the recall and Form 483 cells in FDA's tableSource 3; (5) write down who read it, and when.
Disclosure
Disclosure: Clinic Partner Guide's publisher has undertaken technical and promotional work involving Avanta Pharma Group, which is disclosed as a potential conflict of interest. The publisher holds no ownership stake in Avanta. Avanta is evaluated under the same published scoring methodology as other providers. See our commercial disclosure: https://clinicpartnerguide.com/commercial-disclosure/Source 7
What FDA's own pages say, read 30 October 2026
Quoted from FDA only. Each page's "Content current as of" date is given as printed.
Key takeaways
- Warning Letters (index), content current as of 10/27/2026. "Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the letter recipient that may have changed the regulatory status of issues discussed in the letter."Source 1
- About Warning and Close-Out Letters, content current as of 03/20/2024. A Warning Letter is often how FDA notifies a party when it identifies "what it believes are significant violation(s) of federal requirement(s)". On close-outs: "The corrective actions must actually have been made and verified by FDA."Source 2
- Registered Outsourcing Facilities, content current as of 10/23/2026. "This table lists the outsourcing facilities that have submitted registration information that has been determined to be complete by the data lock date for the latest weekly update of the table." Its columns include "Form 483 Issued?", "Recall Conducted?" and "Action Based on Last Inspection".Source 3
The index adds: "To obtain additional available information, contact FDA."Source 1
Three dates, three fields
A letter and its page carry three dates. They record different things, so keep each in its own field.
Key takeaways
- Letter date. FDA shows it as "Letter Issue Date" in the index, and as the date printed on the letter. Write the date as printed.Source 1
- Posted date. FDA shows it as "Posted Date" in the index. Write the date as printed.Source 1
- "Content current as of". It sits in the footer of the letter page. Write the date as printed, and the day you read it.
FDA's pages we read do not define "Content current as of". Record it as printed, and do not read it as the date of any event.
A missing close-out letter: what it records, and what it does not show
- What to write. FDA's index has a "Closeout Letter" columnSource 1. If nothing is listed against a letter, write "none listed" with the date. That is a fact about the page on that day, and we draw no conclusion from it.
- FDA's conditions for issuing one. "A close-out letter will not be issued based on representations that some action will or has been taken." And: "If the Warning Letter contains violations that by their nature are not correctable, then no close-out letter will issue."Source 2
- Older letters. FDA says the close-out procedure "applies to Warning Letters issued on or after September 1, 2009."Source 2
- A listed close-out has its own caveat. "Future FDA inspections and regulatory activities may further assess the adequacy and sustainability of these corrections."Source 2
The outsourcing-facility table: recall and Form 483 cells
- 503B facilities only. The table sits under section 503B, and the page does not mention 503A pharmaciesSource 3. Our 503A vs 503B guide says: "Look for the facility by name in FDA's Registered Outsourcing Facilities table."Source 6
- The recall cell, in FDA's note. FDA's note on "Recall Conducted?" ties it to inspectional findings: the facility may have started a recall itself, or FDA may have recommended one. It adds: "Additionally, the outsourcing facility may have conducted multiple recalls or recalled multiple drugs."Source 3
- Form 483, in FDA's words. "It does not constitute a final agency determination of whether any condition is in violation of the FD&C Act or any relevant regulations."Source 3
- Weekly, and not the whole record. The table reflects "the latest weekly update of the table". FDA also notes: "This table does not include State Board of Pharmacy actions, if any."Source 3
Five steps, and what to ask the supplier in writing
Any clinic can run these on any supplier, and none is a pass mark. Run them before a first order, and again when you re-check the file.
Ask for the names to search.
In writing: the supplier's legal entity name, any "doing business as" name, and the name of each pharmacy or facility that fills your orders. FDA's index lists letters by "Company Name"Source 1, which may differ from the brand you order from. Keep on file: the names, as written.
Search the warning-letter index by each name.
For each letter found, record the three dates aboveSource 1. If none is found, write "no letter found" and the date. That records one search on one day, nothing more.
Check the close-out and response columns.
Write what is listed, or "none listed", with the date.Source 1
For a 503B facility, copy its row in FDA's table.
The "Form 483 Issued?", "Recall Conducted?" and "Action Based on Last Inspection" cells as printed, with the table's "Content current as of" date.Source 3
Ask the supplier about any entry, in writing.
Ask what it can tell you about the entry, and whether it has received a close-out letter. Keep the reply as written, with who read FDA's pages and when.
The row to keep in your supplier file
Our due-diligence file says "Date each entry and keep its source."Source 4For FDA's pages, keep one row per supplier, and one per filling pharmacy or facility.
Key takeaways
- Name searched. Legal and "doing business as" names, as the supplier gave them.
- Warning letters. Each letter's subject as listed, or "no letter found".
- Three dates. Letter Issue Date, Posted Date, and the page's "Content current as of" date.
- Close-out and response. As listed in the index, or "none listed".
- Outsourcing facility table. For a 503B facility: the Form 483, recall and action cells, with the table's date. For a 503A pharmacy: "not applicable".
- Supplier's reply. The email or letter, dated.
- Read by, and on. Who read FDA's pages, and the date.
A row with nothing found still counts. It shows the search was run, by whom and when.
What this page does not cover
This page is a record-keeping routine. It does not say what a warning letter, close-out, Form 483 or recall means for any supplier, and it draws no conclusion about any pharmacy or facility. That reading belongs to FDA, your state board and your counsel.
FDA's pages are not the whole record: state board actions sit with each board, and FDA's table excludes themSource 3. Nothing here covers products, their quality or their use.
FDA's pages change. Re-read them on the day you file a row, and use our re-check guide for when to look againSource 5.
Questions clinics ask
How do I check whether my compounding pharmacy has an FDA warning letter?
Ask the pharmacy, in writing, for its legal name and any "doing business as" name. Search FDA's warning-letter index by each, and by any other pharmacy that fills your ordersSource 1. Record what you find with the date, including "no letter found".
What does "Content current as of" mean on an FDA letter page?
Does a missing close-out letter mean the issue is unresolved?
We draw no conclusion from it. FDA's index says matters in a letter may have been subject to later interaction that "may have changed the regulatory status of issues discussed in the letter."Source 1FDA's close-out page also sets conditions on issuing oneSource 2. Record "none listed" with the date, and ask the supplier in writing.
Where do I see whether an outsourcing facility conducted a recall?
In the "Recall Conducted?" column of FDA's Registered Outsourcing Facilities table, which lists facilities registered under section 503B. FDA's note ties the column to inspectional findings.Source 3
How often should I re-check?
No source we read sets an interval, and this page sets none. Our re-check guide lists what should make you check sooner, including a newer "Content current as of" date on FDA's pages.Source 5
Sources
- Official primary sourceU.S. Food and Drug AdministrationRetrieved
- Official primary sourceU.S. Food and Drug AdministrationRetrieved
- Official primary sourceU.S. Food and Drug AdministrationRetrieved
- 4The due-diligence file: what to have on record before you sign with a compounding pharmacyclinicpartnerguide.comOfficial primary sourceClinic Partner GuideRetrieved
- 5Keeping the supplier file current: what to capture again, and what should make you check soonerclinicpartnerguide.comOfficial primary sourceClinic Partner GuideRetrieved
- 6503A vs 503B for a med spa or clinic: what to ask a supplier, and how to check the answerclinicpartnerguide.comOfficial primary sourceClinic Partner GuideRetrieved
- Official primary sourceClinic Partner GuideRetrieved
Contents
- How does a clinic look up, and file, what FDA has posted about a supplier?
- In short: five steps
- Disclosure
- What FDA's own pages say, read 30 October 2026
- Key points
- Overview
- Three dates, three fields
- Key points
- Overview
- A missing close-out letter: what it records, and what it does not show
- The outsourcing-facility table: recall and Form 483 cells
- Five steps, and what to ask the supplier in writing
- How it works
- The row to keep in your supplier file
- Key points
- Overview
- What this page does not cover
- Questions clinics ask
- Use it with
- Sources
What each 503A pharmacy partner publishes about pricing
There is no standard 503A compounding pharmacy price for clinics, and the reason is disclosure rather than variation alone: of the 12 sourcing platforms in this index, one publishes actual clinic rates. The rest either describe how pricing works without saying what it costs, or publish nothing about price and quote only after a call. Read as at 2026-08-31, except where a row gives a later date.
| Platform | Clinic pricing | What is published |
|---|---|---|
| Avanta Pharma Group | Rates published | Publishes a full per-vial retail schedule for compounded semaglutide and tirzepatide by concentration and vial size (semaglutide 1 mL at 2.5 mg/mL $80, falling to $65 at 200+ orders a month; tirzepatide from $100 per 1 mL vial), four monthly-volume bands (25-49, 50-99, 100-199, 200+) and an on-site price comparison calculator. List pricing is orderable with no call; volume pricing is quoted on a call.Re-read 2026-10-22 |
 AutoPilotRx | Model only, no rates | States pricing, state licensing and formularies are comparable in-portal and free for providers. No per-clinic negotiated pricing is stated. |
 Fizy Health | Model only, no rates | States pass-through pricing and zero platform fee. Pass-through is the pharmacy price rather than a per-clinic negotiated rate. |
 The Banyan Network | Model only, no rates | Publishes negotiated per-partner rates, net-30 terms, no membership or joining fees, and an all-inclusive definition covering medication, supplies, dispensing fees and shipping. States that rates depend on category, volume and partner, and are fixed in the agreement before a first order. No rate card or tiers are published.Re-read 2026-10-18 |
 CompoundingFinder | Model only, no rates | Compares pharmacies by price, turnaround, shipping and inactive ingredients, free and with no obligation. |
| Peptide Association Pharmacy Directory | Model only, no rates | States price ranges are tracked alongside accreditation and compounds. |
 Find My Chemist | Model only, no rates | Invites submitted prices and shows price information, but not provider-negotiated rates. |
 VitaRelay | Nothing published | No pricing is published; entry is book a call. |
 Ironsail Pharma / ImpetusOne | Nothing published | No pricing is published; the product sits behind a demo. |
| CLR RX | Nothing published | No pricing is published; entry is a private demo request. |
 Find My Compounder | Nothing published | No pricing is published. |
 APC / A4PC Pharmacy Locator | Nothing published | No pricing is published. |
Pricing shown is what each provider published at the time we recorded it and may change. Actual pricing varies by product, formulation, order volume, shipping, pharmacy, location and commercial terms. Confirm current pricing directly with the provider.